Although it is well-established that the oncogene KRAS is the main driver for the acquisition of several cancer features by PDAC cells, whether this oncogene has a relevant role also in the HBP enhancement as compared with PDAC cells expressing wild type KRAS has been less well-addressed and still needs more clarifications. This evidence concerns the gene KRAS and cancer.